



Keytruda® (pembrolizumab) – Expanded indication

- On July 6, 2021, Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or **locally advanced** cSCC that is not curable by surgery or radiation.
 - Keytruda was previously approved in this indication in the recurrent or metastatic setting only.
- Keytruda is also approved for melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer, MSI-H or dMMR colorectal cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, tumor mutational burden-high cancer, and triple-negative breast cancer.
- The approval of Keytruda for the expanded indication was based on KEYNOTE-629, a multi-cohort, non-randomized, open-label study in patients with cSCC. The study included 54 patients with locally advanced cSCC. The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR).
 - The ORR was 50% (95% CI: 36, 64).
 - The median DOR was not reached (range: 1.0+, 17.2+).
- The recommended dose of Keytruda for the treatment of cSCC is 200 mg intravenously every 3 weeks or 400 mg every 6 weeks. Keytruda is administered until disease progression, unacceptable toxicity, or up to 24 months.
 - Refer to the Keytruda drug label for dosing for all its other indications.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.